Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02OJC
|
|||
| Former ID |
DCL000663
|
|||
| Drug Name |
Xaliproden
|
|||
| Synonyms |
Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Juvenile idiopathic arthritis [ICD-11: FA24; ICD-9: 714.3] | Phase 3 | [1] | |
| Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 3 | [1] | ||
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9] | Discontinued in Phase 3 | [2] | ||
| Lateral sclerosis [ICD-11: 8B61] | Discontinued in Phase 3 | [2] | ||
| Peripheral sensory neuropathies [ICD-11: LD27.3; ICD-10: Q84.2] | Discontinued in Phase 3 | [2] | ||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H22F3N
|
|||
| Canonical SMILES |
C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3
|
|||
| InChI |
1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2
|
|||
| InChIKey |
WJJYZXPHLSLMGE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 135354-02-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:48520
|
|||
| SuperDrug ATC ID |
N07XX03
|
|||
| SuperDrug CAS ID |
cas=135354028
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Antagonist | [3] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001601) | |||
| REF 3 | Pharma & Vaccines. Product Development Pipeline. April 29 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.